Autosomal dominant hypercholesterolemia: Needs for early diagnosis and cascade screening in the Tunisian population

Current Genomics

Volumn 14, Issue 1, 2013, Pages 25-32

  Jelassi, Awatef ^a   Najah, Mohamed ^a   Slimani, Afef ^a   Jguirim, Imen ^a   Slimane, Mohamed Naceur ^a   Varret, Mathilde ^b  

^a Research Unit of Genetic and Biological Factors of Atherosclerosis Faculty of Medecine   (Tunisia)

^b INSERM   (France)

Author keywords

Autosomal dominant hypercholesterolemia; Molecular default; Screening protocol

Indexed keywords

APOLIPOPROTEIN B100; BIOLOGICAL FACTOR; CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN;

ARTICLE; AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; MOLECULAR DEFECT; MOLECULAR DYNAMICS; MORBIDITY; PHENOTYPE; PHYSICAL EXAMINATION; RECEPTOR GENE; SCREENING; TUNISIA;

EID: 84888247004     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202911314010004     Document Type: Article

References (68)

1. Muller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand, 1938, 89 sup: 75-84.
2. Brown, M. S; Goldstein, J, L. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232: 34-47.
3. Goldstein, J. L; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 343: 425-30.
4. Goldstein, J.; Brown, M. Familial hypercholesterolemia. In Scriver C, Beaudet A, Sly W, eds. The metabolic basis of inherited diseases. New York: Mc Graw-Hill, 1989: pp1215-1250.
5. Moorjani, S.; Roy, M.; Gagne, C.; Davignon, J.; Brun, D.; Toussaint, M.; Lambert, M.; Campeau, L.; Blaichman, S.; Lupien, P. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis, 1989, 9: 211-216.
6. Seftel, H.C.; Baker, S.G.; Sandler, P., Forman, M.B.; Joffe, B.I.; Mendelsohn, D.; Jenkins, T.; Mieny, C.J. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J, 1980, 281: 633-636.
7. Seftel, H.C.; Baker, S.G.; Jenkins, T.; Mendelsohn, D. Prevalence of familial hyperchoelsterolemia in Johannesburg Jews. Am J Med Genet, 1989, 34: 545-547.
8. Rubinsztein, D.C.; van der Westhyzen, D.R.; Coetzee, G.A. Monogenic primary hypercholesterolemia in South Africa. S Afr Med J, 1994, 84: 339-344.
9. Slack, J. Inheritence of familial hypercholesterolemia. Atheroscler Rev, 1979, 5: 35-66.
10. Vuorio, A.F.; Aalto-Setala, K.; Koivisto, U.M.; Turtola, H.; Nissen, H.; Kovanen, P.T.; Miettinen, T.A.; Gylling, H.; Oksanen, H.; Kontula, K. Familial hypercholesterolemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group. Ann Med, 2001, 33: 401-421.
11. Slimane, M.N.; Pousse, H.; Maatoug, F.; Hammami, M.; Ben Farhat, M.H. Phenotypic expression of familial hypercholesterolemia in central and southern Tunisia. Atherosclerosis, 1993, 104: 153-158.
12. th ed. New York: Mc Graw-Hill; 1995. p.1981-2030.
13. Robles-Osorio, L.; Huerta-Zepeda, A.; Ordonez, M.L.; Canizales-Quinteros, S.; Díaz-Villaseñor, A.; Gutiérrez-Aguilar, R.; Riba, L.; Huertas-Vázquez, A.; Rodríguez-Torres, M.; Gómez-Díaz, R.A.; Salinas, S.; Ongay-Larios, L.; Codiz-Huerta, G.; Mora-Cabrera, M.; Mehta, R.; Gómez Pérez, F.J.; Rull, J.A.; Rabès, J.P.; Tusié-Luna, M.T.; Durán-Vargas, S.; Aguilar-Salinas, C.A. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico. Arch Med Res, 2006, 37: 102-108.
14. Marques-Pinheiro, A.; Marduel, M.; Rabès, J.P.; Devillers, M.; Villéger, L.; Allard, D.; Weissenbach, J.; Guerin, M.; Zair, Y.; Erlich, D.; Junien, C.; Munnich, A.; Krempf, M.; Abifadel, M.; Jaïs, J.P.; French Research Network on ADH, Boileau, C.;, Varret, M. A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1. Eur J Hum Genet, 2010, 18: 1236-1242.
15. Wang, X.; Li, X.; Zhang, Y.B.; Zhang, F.; Sun, L.; Lin, J.; Wang, D.M.; Wang, L.Y. Genome-wide linkage scan of a pedigree with familial hypercholesterolemia suggests susceptibility loci on chromosomes 3q25-26 and 21q22. PLoS One, 2011; 6: e24838.
16. Cenarro, A.; Garcia-Otin, A.L.; Tejedor, M.T.; Solanas, M.; Jarauta, E.; Junquera, C.; Ros, E.; Mozas, P.; Puzo, J.; Pocoví, M.; Civeira, F. A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clin Genet, 2011, 79: 475-481.
17. Marks, D.; Thorogood, M.; Neil, H.A.; Humphries, S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. Atherosclerosis, 2003, 168: 1-14.
18. Williams, R.R.; Hunt, S.C.; Schumacher, M.C.; Hegele, R.A.; Leppert, M.F.; Ludwig, E.H.; Hopkins, P.N. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol, 1993, 72: 171-176.
19. Goldstein, J.L.; Hobbs, H.H.; Brown, M.S. Familial hypercholesterolemia. In Scriver CR, Beaudet A, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited diseases. Volume III. New York: Mc Graw-Hill, 2001. p.2863-2914.
20. Marais, D. Familial hypercholesterolemia. Clin Biochem Rev, 2004, 25: 49-68.
21. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering on behalf the Simon Broome Register Group. BMJ, 1991, 303: 893-896.
22. Mortality in treated heterozygous familial hypercholesterolemia: implication for clinical management. Scientific Steering on behalf the Simon Broome Register Group. Atherosclerosis, 1999, 142: 105-112.
23. World Health Organisation. Familial hypercholesterolemia-report of a second WHO Consultation. Geneva, Switzerland; World Health Organisation, 1999. (WHO publication no WHO/HGN/ FH/CONS/99.2)
24. Jelassi, A.; Slimani, A.; Jguirim, I.; Najah, M.; Abid, A.; Boughamoura, L.; Mzid, J.; Fkih, M.; Maatouk, F.; Rouis, M.; Varret, M.; Slimane, M.N. Moderate phenotypic expression of familial hypercholesterolemia in Tunisia. Clinica Chimica Acta, 2010, 411: 735-738.
25. Cai, H.J.; Fan, L.M.; Huang, M.G.; Chen, X.Y.; Liu, G.Q.; Chen, Q. Homozygous familial hypercholesterolemic patients in China. Atherosclerosis, 1985, 57: 303-312.
26. Mabuchi, H.; Tatami, R.; Haba, T.; Ueda, K.; Ueda, R.; Kametani, T.; Itoh, S.; Koizumi, J.; Oota, M.; Miyamoto, S.; Takeda, R.; Takeshita, H. Homozygous familial hypercholesterolemia in Japan. Am J Med, 1978, 65: 290-297.
27. Sun, X.M.; Patel, D.D.; Knight, B.L.; Soutar, A.K. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia, the familial hypercholesterolaemia regression study group. Atherosclerosis, 1998, 136: 175-185.
28. Kotze, M.J.; DeVilliers, W.J.S.; Steyn, K.; Kriek, J.A.; Marais, A.D.; Langenhoven, E.; Herbert, J.S.; Graadt Van Roggen, J.F.; Van der Westhuyzen, D.R.; Coetzee, G.A. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb, 1993, 13: 1460-1468.
29. Bertolini, S.; Cantafora, A.; Averna, M.; Cortese, C.; Motti, C.; Martini, S.; Pes, G.; Postiglione, A.; Stefanutti, C.; Blotta, I.; Pisciotta, L.; Rolleri, M.; Langheim, S.; Ghisellini, M.; Rabbone, I.; Calandra, S. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol, 2000, 20: e41-52.
30. Slimani, A.; Jelassi, A.; Jguirim, I.; Najah, M.; Rebhi, L.; Omezzine, A.; Maatouk, F.; Hamda, K.B.; Kacem, M.; Rabès, J.P.; Abifadel, M.; Boileau, C.; Rouis, M.; Slimane, M.N.; Varret, M. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis, 2012, 222: 158-166.
31. Goldstein, J.L.; Brown, M.S.; Anderson, R.G.; Russell, D.W.; Schneider, W.J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol, 1985, 1: 1-39.
32. Hobbs, H.H.; Russell, D.W.; Brown, M.S.; Goldstein, J.L. The LDL receptor locus and familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet, 1990, 24: 133-170.
33. Yamamoto, T.; Davis, C.G.; Brown, M.S.; Schneider, W.J.; Casey, M.L.; Goldstein, J.L.; Russell, D.W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell, 1984, 39: 27-38.
34. Soutar, A.K.; Naoumova, R. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nature, 2007, 4: 214-225.
35. Graham, C.A.; McIlhatton, B.P.; Krik, C.W.; Beattie, E.D.; Lyttle, K.; Hart, P.; Neely, R.D.; Young, I.S.; Nicholls, D.P. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis, 2005, 182: 331-340.
36. Kane, J.; Havel, R. Disorders of the biogenesis and secretion of lipoprotein containing the B apolipoproteins. In Scriver C, Beaudet A, Sly W, eds. The metabolic and molecular basis of inherited diseases. New York: Mc Graw-Hill, 1995, pp, 1853-1886.
37. Knott, T.J.; Pease, R.J.; Powell, L.M.; Wallis, S.C.; Rall, S.C. Jr.; Innerarity, T.L.; Blackhart, B.; Taylor, W.H.; Marcel, Y.; Milne, R. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature, 1986, 323: 734-738.
38. Law, A.; Scott, J. A cross-species comparison of the apolipoprotein B domain that binds to the LDL receptor. J Lipid Res, 1990, 31: 1109-1120.
39. Innerarity, T.L.; Weisgraber, K.H.; Arnold, K.S.; Mahley, R.W.; Krauss, R.M.; Vega, G.L.; Grundy, S.M.; et al. Familial defective apolipoprotein B-1low density lipoproteins with abnormal receptor binding. Proc Natl Acad sci USA, 1987, 84: 6919-6923.
40. Soria, L.F.; Ludwig, E.H.; Clarke, H.R.; Vega, G.L.; Grundy, S.M.; McCarthy, B.J. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad sci USA, 1989, 86: 587-591.
41. Dunning, A.M.; Houlston, R.; Frostegård, J.; Revill, J.; Nilsson, J.; Hamsten, A.; Talmud, P.; Humphries, S. Genetic evidence that the putative receptor binding domain of apolipoprotein B (residues 3130 to 3630) is not the only region of the protein involved in interaction with the low density lipoprotein receptor. Biochim Biophys Acta, 1991, 1096: 231-237.
42. Boren, J.; Ekstrom, U.; Agren, B.; Nilsson-Ehle, P.; Innerarity, T.L. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem, 2001; 276: 9214-9218.
43. Myant, N.B. Familial defective apolipoprotein B-1a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis, 1993, 104:, 1-18.
44. Vrablík, M.; Ceska, R.; Horínek, A. Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis. Physiol Res, 2001, 50: 337-343.
45. Abifadel, M.; Varret, M.; Rabès, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003, 34: 154-156.
46. Seidah, N.G.; Chretien, M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res, 1999, 848: 45-62.
47. Seidah, N.G.; Benjannet, S.; Wickham, L.; Marcinkiewicz, J.; Jasmin, S.B.; Stifani, S.; Basak, A.; Prat, A.; Chretien, M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A, 2003, 100: 928-933.
48. Naureckiene, S.; Ma, L.; Sreekumar, K.; Purandare, U.; Lo, C.F.; Huang, Y.; Chiang, L.W.; Grenier, J.M.; Ozenberger, B.A.; Jacobsen, J.S.; Kennedy, J.D.; DiStefano, P.S.; Wood, A.; Bingham, B. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys, 2003, 420: 55-67.
49. Basak A. Inhibitors of proprotein convertases. J Mol Med (Berl), 2005, 83: 844-855.
50. Benjannet, S.; Rhainds, D.; Hamelin, J.; Nassoury, N.; Seidah, N.G. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem, 2006; 281: 30561-30572.
51. Moore, K.L. The biology and enzymology of protein tyrosine Osulfation. J Biol Chem, 2003, 278: 24243-24246.
52. Timms, K.M.; Wagner, S.; Samuels, M.E.; Forbey, K.; Goldfine, H.; Jammulapati, S.; Skolnick, M.H.; Hopkins, P.N.; Hunt, S.C.; Shattuck, D.M. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet, 2004, 114: 349-353.
53. Park, S.W.; Moon, Y.A.; Horton, J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/ kexin type 9a in mouse liver. J Biol Chem, 2004, 279: 50630-50638.
54. Varret, M.; Abifadel, M.; Rabès, J.P.; Boileau, C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet, 2008, 73: 1-13.
55. Cohen, J.; Pertsemlidis, A.; Kotowski, I.K.; Graham, R.; Garcia, C.K.; Hobbs, H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet, 2005, 37: 161-165.
56. Cameron, J.; Holla, O.L.; Ranheim, T.; Kulseth, M.A.; Berge, K.E.; Leren, T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet, 2006, 15: 1551-1558.
57. Kotowski, I.K.; Pertsemlidis, A.; Luke, A.; Cooper, R.S.; Vega, G.L.; Cohen, J.C.; Hobbs, H.H. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet, 2006, 78: 410-422.
58. Rashid, S.; Curtis, D. E.; Garuti, R.; Anderson, N.N.; Bashmakov, Y.; Ho, Y.K.; Hammer, R.E.; Moon, Y.A.; Horton, J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A, 2005, 102: 5374-5379.
59. Frank-Kamenetsky, M.; Grefhorst, A.; Anderson, N.N.; Racie, T.S.; Bramlage, B.; Akinc, A.; Butler, D.; Charisse, K.; Dorkin, R.; Fan, Y.; Gamba-Vitalo, C.; Hadwiger, P.; Jayaraman, M.; John, M.; Jayaprakash, K.N.; Maier, M.; Nechev, L.; Rajeev, K.G.; Read, T.; Röhl, I.; Soutschek, J.; Tan, P.; Wong, J.; Wang, G.; Zimmermann, T.; de Fougerolles, A.; Vornlocher, H.P.; Langer, R.; Anderson, D.G.; Manoharan, M.; Koteliansky, V.; Horton, J.D.; Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman pri-mates. Proc Natl Acad Sci U S A, 2008, 105: 11915-11920.
60. Ni, Y.G.; Di Marco. S.; Condra, J.H.; Peterson, L.B.; Wang, W.; Wang, F.; Pandit, S.; Hammond, H.A.; Rosa, R.; Cummings, R.T.; Wood, D.D.; Liu, X.; Bottomley, M.J.; Shen, X.; Cubbon, R.M.; Wang, S.P.; Johns, D.G.; Volpari, C.; Hamuro, L.; Chin, J.;Huang, L.; Zhao, J.Z.; Vitelli, S.; Haytko, P.; Wisniewski, D.; Mitnaul, L.J.; Sparrow, C.P.; Hubbard, B.; Carfí, A.; Sitlani, A. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol. J Lipid Res, 2011, 52: 78-86.
61. Zhang, L.; McCabe, T.; Condra, J.H.;, Ni, Y.G.; Peterson, L.B.; Wang, W.; Strack, A.M.; Wang, F.; Pandit, S.; Hammond, H.; Wood, D.; Lewis, D.; Rosa, R.; Mendoza, V.; Cumiskey, A.M.; Johns, D.G.; Hansen, B.C.; Shen, X.; Geoghagen, N.; Jensen, K.; Zhu, L.; Wietecha, K.; Wisniewski, D.; Huang, L.; Zhao, J.Z.; Ernst, R.; Hampton, R.; Haytko, P.; Ansbro, F.; Chilewski, S.; Chin, J.; Mitnaul, L.J.; Pellacani, A.; Sparrow, C.P.; An, Z.; Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci, 2012, 8, 310-327.
62. Medeiros, A.M.; Alves, A.C.; Francisco, V.; Bourbon, M. Investigators of the Portuguese FH Study Update of the Portuguese Familial Hypercholesterolaemia Study. Atherosclerosis, 2010, 212, 553-558.
63. Jelassi, A.; Najah, M.; Jguirim, I.; Maatouk, F.; Lestavel, S.; Laroussi, O.S.; Rouis, M.; Boileau, C.; Rabès, J.P.; Varret, M.; Slimane, M.N. A novel splice site mutation of the LDL receptor gene in a Tunisian hypercholesterolemic family. Clin Chim Acta, 2008, 392: 25-29.
64. Jelassi, A.; Jguirim, I.; Najah, M. Abid, A.M.; Boughamoura, L.; Maatouk, F.; Rouis, M.; Boileau, C.; Rabès, J.P.; Slimane, M.N.; Varret, M. Limited mutational heterogeneity in the LDLR gene in familial hypercholesterolemia in Tunisia. Atherosclerosis, 2009, 203: 449-453.
65. Abifadel, M.; Rabès, J.P.; Jambart, S.; Halaby, G.; Gannagé-Yared, M.H.; Sarkis, A.; Beaino, G.; Varret, M.; Salem, N.; Corbani, S.; Aydénian, H.; Junien, C.; Munnich, A.; Boileau, C. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat, 2009, 30: E682-91.
66. Chater, R.; Aït Chihab, K.; Rabès, J.P.; Varret, M.; Chabraoui, L.; El Jahiri, Y.; Adlouni, A.; Boileau, C.; Kettani, A.; El Messal, M. Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco. Clin Chim Acta, 2006, 373: 62-69.
67. Bertolini, S.; Pisciotta, L.; DiScala, L.; Langheim, S.; Bellocchio, A.; Masturzo, P.; Cantafora, A.; Martini, S.; Averna, M.; Pes, G.; Stefanutti, C.; Calandra, S. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis, 2004, 174: 57-65.
68. Setia, N.; Verma, I. C.; Khan, B.; Arora, A. Premature Coronary Artery Disease and Familial Hypercholesterolemia: Need for Early Diagnosis and Cascade Screening in the Indian Population. Cardiol Res Pract, 2012, 658526.